ArticleEpidemiologia (Basel, Switzerland)2025
Development of Novel Symptom Score to Assist in Screening for Exocrine Pancreatic Insufficiency.
Article in Epidemiologia (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExocrine pancreatic insufficiency (EPI or PEI) often goes undiagnosed or misdiagnosed due to nonspecific symptomatology. Clinicians may focus primarily on symptoms like diarrhea and steatorrhea, potentially overlooking more prevalent symptoms.
methodsOur research describes the development and evaluation of the Exocrine Pancreatic Insufficiency Symptom Score (EPI/PEI-SS), a novel patient-generated symptom score designed to capture a wide range of EPI-related symptoms and quantify symptoms based on frequency and severity (score ranges 0-225). This preliminary real-world study assessed the efficacy of the EPI/PEI-SS in differentiating between individuals with and without EPI. To examine disparities between participants with and without EPI, average symptom frequency, severity, and overall score relationships were assessed, as well as sub-analyses based on other health co-conditions.
resultsIn total, 324 participants (155 with EPI and 169 without) completed the EPI/PEI-SS online. Individuals with EPI reported significantly higher EPI/PEI-SS scores (98.11, range 1-213) indicating a greater symptom burden compared with those without EPI (38.86, range 0-163).
conclusionsThe EPI/PEI-SS appears to effectively differentiate between EPI and non-EPI participants, including non-EPI participants with other GI conditions. The EPI/PEI-SS demonstrates the potential to identify EPI and distinguish symptoms of EPI from other GI conditions, as evaluated with frequency and severity. Future research could replicate the study alongside fecal elastase testing, to determine whether it can be used additionally or alternatively for EPI diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.